A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

NCT05483439 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Stage II-III Breast Cancer

Interventions

DRUG: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
DRUG: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
DRUG: traditional herbal medicine

Sponsor

Shengjing Hospital